Fixed-Duration vs. Continuous-Duration CLL Medicines with Dr. Alvaro Alencar
When faced with choosing a CLL treatment, which do you choose? Become a more informed patient by learning about the differences between fixed-duration and continuous-duration CLL therapies from Dr. Alvaro Alencar! If you are unable to attend the event but have a question for Dr. Alencar, please email cll@healthtree.org.
Megan introduces the agenda of the event and featured speaker Dr. Alvaro Alencar.
Dr. Alencar shares insight about the differences between fixed-duration and continuous-duration CLL medicines.
Type your questions in the chat, and Dr. Alencar will answer them!
Alvaro Alencar, M.D.
Dr. Alencar is an Associate Professor of Clinical Medicine and the Chief Medical Officer at University of Miami Sylvester Comprehensive Cancer Center. He is a member of the lymphoma program at Sylvester and the lymphoma committee at the Alliance for Clinical Trials in Oncology. As the hematology section lead for the Sylvester’s Global Oncology Program, Dr. Alencar serves as an important bridge to the United States for Latin American hematologists being a constant presence in meetings, lectures, as well as tumor board and second opinions. These collaborations have led to a large multinational study evaluating the impact of genetic changes and ancestry on outcomes of Hispanic patients with blood disorders.
Megan Heaps
Megan joined HealthTree as the Program Manager for CLL in 2022. She is the daughter of a blood cancer patient and has found a passion for helping support patients and caregivers to advance research for their cure and improve their quality of life.